Schmerztherapie entzündlich-rheumatischer Erkrankungen

Schlüsselwörter

Schmerz - Arthritis - NSAR - Opioide

Keywords

pain - arthritis - NSAID - opioids

• Literatur

• 1 Arendt-Nielsen L, Olesen AE, Staahl C et al. Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Anesthesiology 2009; 111: 616-624
• 2 Brunnmüller U, Zeitker H, Alten R et al. Wirksame Schmerztherapie mit Tilidin/Naloxon retard bei Patienten mit rheumatoider Arthritis. Aktuelle Rheumatologie 2004; 29: 35-39
• 3 Buynak R, Shapiro DY, Okamoto A et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010; 11: 1787-1804
• 4 Elliott AM, Smith BH, Penny KI et al. The epidemiology of chronic pain in the community. Lancet 1999; 354: 1248-1252
• 5 Fink DJ, Wechuck J, Mata M et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol 2011; 70: 207-212
• 6 Galvez R, Schafer M, Hans G et al. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Adv Ther 2013; 30: 229-259
• 7 Häuser W, Bock F, Engeser P et al. Long-term opioid use in non-cancer pain. Dtsch Artzebl Int 2014; 111: 732-740
• 8 Hewlett S, Sanderson T, May J et al. 'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count – an international patient perspective on flare where medical help is sought. Rheumatology (Oxford) 2012; 51: 69-76
• 9 Hua S, Cabot PJ. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition. Pain Physician 2013; 16: E199-216
• 10 Hughes FM, Shaner BE, Brower JO et al. Development of a Peptide-derived orally-active kappa-opioid receptor agonist targeting peripheral pain. Open Med Chem J 2013; 7: 16-22
• 11 Korotkova M, Jakobsson PJ. Persisting eicosanoid pathways in rheumatic diseases. Nat Rev Rheumatol 2014; 10: 229-241
• 12 Lee YC, Lu B, Boire G et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis 2013; 72: 949-954
• 13 Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther 2011; 13: 211
• 14 Lindhardsen J, Gislason GH, Jacobsen S et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2014; 73: 1515-1521
• 15 Schneider M, Lelgemann M, Abholz H-H et al. Interdisziplinäre Leitlinie: Management der frühen rheumatoiden Arthritis. In: S3-Leitlinie zum Management der frühen Rheumatoiden Arthritis 2011
• 16 Stein C, Baerwald C. Opioids for the treatment of arthritis pain. Expert Opin Pharmacother 2014; 15: 193-202
• 17 Stein C, Kuchler S. Targeting inflammation and wound healing by opioids. Trends Pharmacol Sci 2013; 34: 303-312
• 18 Whittle SL, Richards BL, Husni E et al. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev 2011; CD003113 DOI: 10.1002/14651858.CD003113.pub3.
• 19 Wolfe F, Hauser W, Hassett AL et al. The development of fibromyalgia – I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 2011; 152: 291-299